Evidence map›Paper›PMID 20967819›Full record

ArticleChemMedChem2010

Polycyclic N-benzamido imides with potent activity against vaccinia virus.

Eva Torres, María D Duque, Pelayo Camps, Lieve Naesens, Teresa Calvet, Mercè Font-Bardia, Santiago Vázquez

Abstract read
In one paragraph

Article in ChemMedChem, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eva TorresInstitute of Biomedicine, Universitat de Barcelona, Spain.
María D Duque
Pelayo Camps
Lieve Naesens
Teresa Calvet
Mercè Font-Bardia
Santiago Vázquez

Funding

NIAID NIH HHS AI 062540-01
6 · The paper itself

Abstract

The synthesis and antiviral activity of a series of novel polycyclic analogues of the orthopoxvirus egress inhibitor tecovirimat (ST-246) is presented. Several of these compounds display sub-micromolar activity against vaccinia virus, and were more potent than cidofovir (CDV). The more active compounds were about 10-fold more active than CDV, with minimum cytotoxic concentrations above 100 μM. Chemical manipulations of the two carbon-carbon double bonds present in the compounds were carried out to further explore the structure-activity relationships of these new polycyclic imides. Hydrogenation of the two carbon-carbon double bonds decreases antiviral activity, whereas either cyclopropanation or epoxidation of the double bonds fully eliminates the antiviral activity.

Indexed as

Antiviral AgentsBenzamidesCrystallography, X-RayDrug DesignImidesIsoindolesMolecular ConformationPhthalimidesPolycyclic CompoundsStructure-Activity RelationshipVaccinia virusAntiviral AgentsBenzamidesImidesIsoindolesPhthalimidesPolycyclic Compoundstecovirimat

Identifiers

PMID20967819
PMCPMC7162373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.